Whitehawk Therapeutics, Inc. (WHWK): Total Liabilities
$14.52M
As of 2025-12-31
$11.07M
As of 2026-06-30
-17.5%
3-year compound annual growth
-14.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.52M | -18.6% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $17.84M | -34.5% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $27.23M | +5.3% | 2025-03-28, Balance as of period end |
| 2022-12-31 | $25.86M | +20.3% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $21.50M | -31.2% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $31.26M | +818.9% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $3.40M | -37.7% | 2021-03-11, Balance as of period end |
| 2018-12-31 | $5.46M | n/a | 2020-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Immunome Inc. (IMNM) | 2025-12-31 | $48.84M | -17.3% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $62.07M | -5.7% |
Compare WHWK, OVID, IMNM, XENE side by side · Screen every company in Pharmaceutical Preparations ↗